Диссертация (1141228), страница 20
Текст из файла (страница 20)
2009; 123: 436 -443.94.Kohler M. Thrombogenicity of prothrombin complex concentrates. ThrombRes. 1999;95:S13–7.95.Laporte S., Tardy B., Quenet S., Buchmuller-Cordier A., Chabaud S., EpinatM., Decousus H., Mismetti P. The location of deep-vein thrombosis as a predictivefactor for recurrence and cancer discovery after proximal deep-vein thrombosis.Haematologica . 2003; 88: ELT08.96.Lee A.Y., Levine M.N.
Venous thromboembolism and cancer: risks andoutcomes. Circulation 2003;107(23 Suppl 1):I17-I21.97.Leissinger C.A., Blatt P.M., Hoots W.K., Ewenstein B. Role of prothrombincomplex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol. 2008;83:137–43.98.Levy J.H., Tanaka K.A., Dietrich W. Perioperative hemostatic managementof patients treated with vitamin K antagonists. Anesthesiology. 2008; 109:918–926.99.Limdi N.A., McGwin G., Goldstein J.A., Beasley T.M. et al. Influence ofCYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African- American and European-American patients on warfarin. MolTher. 2008;83:312– 321.100. Lip G.Y., Andreotti F., Fauchier L.
et al. Bleeding risk assessment andmanagement in atrial fibrillation patient. Executive summary of a positiondocument from the European Heart Rhythm Assosiation [EHRA], endorsed by theEuropean Society of Cardiology [ESC] Working Group on Thrombosis. ThrombHaemost. 2011; 106 (6): 997- 1011.101. Liumbruno G., Bennardello F., Lattanzio A. Оn behalf of the Italian Socie-tyof Transfusion Medicine and Immunohematology (SIMTI) Recommenda-tions for116the use of antithrombin concentrates and prothrombin complex con-centrates.Blood Transfus. 2009;7:325–34.102.
Lubetsky A., Hoffman R., Zimlichman R. et al. Efficacy and safety of aProthrombin Complex Concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res. 2004; 113:371–378.103. Lubetsky A., Yonath H., Olchovsky D., Loebstein R., Halkin H., Ezra D.Comparison of oral vs intravenous phytonadione (vitamin K1) in patients withexcessive anticoagulation: a prospective randomized controlled study. Arch In-ternMed. 2003;16320:2469-2473.104.
Makris M., Greaves M., Phillips W.S. et al. Emergency oral anticoagulantreversal: the relative efficacy of infusions of fresh frozen plasma and clottingfactor concentrate on correction of the coagulopathy. Thromb Haemost.1997;77:477–80.105. Makris M., van Veen J., Maclean R. Warfarin anticoagulation reversal:management of the asymptomatic and bleeding patient. J Thromb Thrombo-lysis.2010;;29:171–181.106. Makris M., Watson H.G. The management of coumarin-induced overanticoagulation. Br J Haematol.
2001;;114:271–280.107. Makris M. Optimisation of the Prothrombin Complex Concentrate dose forwarfarin reversal. Thromb Reversal. 2005;;115:451–453.108. Makris M. Optimisation of the prothrombin complex concentrate dose forwarfarin reversal. Thromb Res. 2005;115:451–3.109. Maria I.A., Robert G. H. et al.
Treatment of warfarin- associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clinic Proceeding. 2007; 82: 189- 92.110. Marzia Angelo, Bernhard Gutmann, Michele Adami, Bernd Zagler, AntonZelger, Christoph Pechlaner, Christian J. Wiedermann. Emergen-cy correction of117coagulation before major surgery in two elderly patients on oral anticoagulation.Thromb J. 2007; 5: 1.111. Maurer-Spurej E., Pittendreigh C., Solomons K. The influence of selectiveserotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost2004;91:119-28.112.
McClain M., Palomaki G., Piper M., Haddow J.E. A Rapid-ACCE review ofCYP2C9 and VKORC1 allele testing to inform warfarin dosing in adults atelevated risk for thrombotic events to avoid serious bleeding. Genet Med.2008;10:89–98.113. McСowan Т. Complications оf the nitinol vena caval filter / [et аl.] // J.Vasc. Interv. Radiol. - 1992. - Vol. 3, N 2. - Р. 401-408.114. Электронныйресурс–режимдоступа:ресурсmedind.nic.in/jac/t14/i1/jact14i1p75.pdf.115. Meena Zareh, Andrew Davis, Sean Henderson.
Reversal of WarfarinInduced Hemorrhage in the Emergency Department. West J Emerg Med. 2011Nov; 12(4): 386–392.116. Oake N., Jennings A., Forster A.J. et al. Anticoagulation intensity andoutcomes among patients prescribed oral anticoagulant therapy: a systematicreview and meta- analysis.
CMAJ. 2008; 179 (3): 235- 244.117. Ostermann H., Haetrel S., Knaub S. et al. Pharmacokinetics of Beriplex P/NProthrombin Complex Concentrate in healthy volunteers. Thromb Hae-most. 2007;98:790–797.118. Palareti G., Cosmi B. Bleeding with anticoagulation therapy- who is at risk,and how to best identify such patients. Thromb Haemost. 2009; 102 (2): 268- 278.119. Pengo V., Lensing A.W., Prins M.H., Marchiori A., Davidson B.L., TiozzoF., Albanese P., Biasiolo A., Pegoraro C., Iliceto S., Prandoni P.
Incidence ofchronic thromboembolic pulmonary hypertension after pulmonary embolism. NEngl J Med. 2004; 350: 2257 -2264.118120. Pesavento R., Bernardi E., Concolato A., Dalla Valle F., Pagnan A., Prandoni P. Postthrombotic syndrome. Semin Thromb Hemost. 2006; 32: 744–751.121. Philip S. Wells., Melissa A. Forgie, Marc A. Rodger. Treatment of Ve-nousThromboembolism.
JAMA. 2014;311(7):717-728.122. Prandoni P., Lensing A.W., Piccioli A., Bernardi E., Simioni P., GirolamiB., Marchiori A., Sabbion P., Prins M.H., Noventa F., Girolami A. Recurrentvenous thromboembolism and bleeding complications during anticoagulanttreatment in patients with cancer and venous thrombosis.
Blood. 2002; 100: 3484 3488.123. Prandoni P., Noventa F., Ghirarduzzi A., Pengo V., Bernardi E., Pe-saventoR. et al. The risk of recurrent venous thromboembolism after discon-tinuinganticoagulation in patients with acute proximal deep vein thrombosis or pulmonaryembolism. A prospective cohort study in 1626 patients. Haematologica 2007; 91 :199-205.124.
Rose A.J., Ozonoff A., Berlowitz D.R. et al. Prompt repeat testing after outof- range INR values: a quality indicator for anticoagulation care. Circ CardiovaskQual Outcomes. 2011; 4 (3): 276- 282.125. Rose A.J., Ozonoff A., Berlowitz D.R.
et al. Reexamining the recommended follow up interval after obtaining an in- range international normalizedratio value: results from the Veterans Affairs study to improve anticoagula-tion.Chest. 2011; 140 (2): 359- 365.126. Rose A.J., Ozonoff A., Berlowitz D.R., Henault L.E., Hylek E.M. Warfa-rindose management affects INR control. J. Thromb Haemost. 2009; 7(1): 94- 101.127. Rosovsky R.P., Crowther M.A. What is the evidence for the off-label use2008; 36–38.128. Rowe S., Turner R.M.
Coagulation Factor VIIa (recombinant) for warfa-rininduced intracranial hemorrhage. Am J Health-Syst Pharm. 2010;;67:361–365.129. Safaoui M., Aazami R., Hotz H. et al. A promising new alternative for the119rapid reversal of warfarin coagulopathy in traumatic intracranial hemorrhage. Am JSurg. 2009; 197:785–790.130. Salem D.N., Stein P.D., Al-Ahmad A. et al Antithrombotic therapy in valvular heart disease-native and prosthetic: the Seventh ACCP Conference onAntithrombotic and Thrombolytic Therapy. Chest 2004 126 (Suppl) S457S482.S482.131. Schulman S., Bijsterveld N.R.
Anticoagulants and their reversal. Transfusion Med Rev. 2007; 1:37–48.132. Schulman S. Care of patients receiving long-term anticoagulant therapy. NEngl J Med. 2003;;349:675–683.133. Shireman T.I., Mahnken J.D., Howard P.A., Kresowik T.F., Hou Q.,Ellerbeck E.F. Development of a contemporary bleeding risk model for elderlywarfarin recipients. Chest. 2006; 13 (5): 1390- 1396.134.Shorr R.I., Ray W.A., Daugherty J.R., Griffin M.R..
Concurrent use of non-steroidal anti-inflammatory drugs and oral anticoagulants places elderly per-sons athigh risk for hemorrhagic peptic ulcer disease. Arch Intern Med. 1993;153:1665–70.135. Singer D.E., Albers G.W., Dalen J.E., Go A.S., Halperin J.L., Manning W.J.Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference onAntithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):429S–456S.136. Spahn D.R., Cerny V., Coats T.J. et al.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
